PIP Search Page

Displaying 21 - 40 of 107

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Date Published Sort ascending
MHRA-100873-PIP01-23	Meningococcal Group A, C, W-135 and Y conjugate vaccine	Meningococcal meningitis	Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo Menveo	Vaccines	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/12/2023
MHRA-101019-PIP01-23	Treprostinil Palmitil	Treatment of pulmonary hypertension due to lung disease and/or hypoxia.	Not available at present	Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/12/2023
MHRA-100933-PIP01-23	camlipixant	Treatment of unexplained or chronic refractory cough		Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/12/2023
MHRA-100832-PIP01-23-M01 (update)	LANADELUMAB	Prevention of attacks of idiopathic non-histaminergic angioedema (INHA).	TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO TAKHZYRO	Other: Genetic disease	W: decision granting a waiver in all age groups for the listed condition(s).	No	24/08/2023
MHRA-100801-PIP01-22	eplontersen	Treatment of transthyretin-mediated amyloidosis	Not available at present	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	24/08/2023
MHRA-100806-PIP01-22	ALPELISIB	Treatment of ovarian cancer (excluding rhabdomyosarcoma and germ cell tumours) Treatment of Fallopian cancer (excluding rhabdomyosarcoma and germ cell tumours) Treatment of Peritoneal cancer (excluding blastomas and sarcomas).	Piqray Piqray	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	24/08/2023
MHRA-100301-PIP02-22	Nipocalimab	Treatment of Bullous Pemphigoid		Dermatology	W: decision granting a waiver in all age groups for the listed condition(s).	No	24/08/2023
MHRA-100738-PIP01-22	PEMIGATINIB	Treatment of myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement	Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	24/08/2023
MHRA-100740-PIP01-22	Xevinapant	Treatment of head and neck epithelial malignant neoplasms	Not available at present	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100029-PIP01-21-M01 (update)	RECOMBINANT REPLICATION-INCOMPETENT ADENOVIRUS SEROTYPE 26 VECTOR ENCODING THE SARS-COV-2 SPIKE PROTEIN PER.C6 CELL LINE COVID-19 vaccine (Ad26.COV2-S [recombinant])	Prevention of coronavirus disease-2019 (COVID-19)	COVID-19 vaccine Janssen Jcovden (previously COVID-19 Vaccine Janssen)	Infectious diseases Vaccines	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100699-PIP01-22-M01 (update)	DIROXIMEL FUMARATE	Treatment of Multiple Sclerosis	Vumerity Vumerity Vumerity	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100733-PIP01-22	Botulinum toxin type E	Treatment of skin wrinkling		Dermatology	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100684-PIP01-22	Clazakizumab	Prevention of cardiovascular events in patients with atherosclerosis	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100598-PIP01-22	Cobolimab	Treatment of lung cancer	Not available at present	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100587-PIP01-22	lusvertikimab	Treatment of Sjögren’s syndrome		Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100577-PIP01-22	ziltivekimab	Treatment of heart failure	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100603-PIP01-22	Oleclumab	Treatment of lung cancer Treatment of pancreatic cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100602-PIP01-22	monalizumab	Treatment of lung cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100583-PIP01-22	SACITUZUMAB GOVITECAN	Treatment of lung carcinoma (small-cell and non-small-cell carcinoma)	Trodelvy Trodelvy Trodelvy	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100599-PIP01-22	Flortaucipir F18	Diagnosis of Alzheimer's disease	Tauvid Tauvid	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023

Download XLSX

Search Filters: